Table 3 Odds Ratio for Fracture, Indirect Treatment Comparison between drugs (Bayesian analysis)

Denosumab vs Alendronate

0.99 (0.72, 1.42)

1,063

0.63 (0.38, 0.97)

26

1.30 (0.38, 3.35)

-180

NR

NR

Denosumab vs Etidronate

1.26 (0.59, 2.69)

-42

0.58 (0.26, 1.15)

23

1.43 (0.13, 5.97)

-126

NR

NR

Denosumab vs Ibandronate

0.89 (0.61, 1.31)

96

0.67 (0.35, 1.19)

30

NR

NR

NR

NR

Denosumab vs Raloxifene

0.87 (0.59, 1.30)

81

0.51 (0.29, 0.83)

20

0.71 (0.14, 1.89)

184

NR

NR

Denosumab vs Risedronate

1.04 (0.76, 1.54)

-267

0.53 (0.32, 0.82)

21

0.94 (0.27, 2.24)

893

NR

NR

Denosumab vs Teriparatide

1.29 (0.73, 2.26)

-38

1.06 (0.50, 1.99)

-169

3.24 (0.17, 16.89)

-25

NR

NR

Denosumab vs Zoledronic Acid

1.08 (0.73, 1.62)

-134

1.16 (0.66, 1.88)

-65

1.36 (0.30, 3.48)

-150

NR

-14

Etidronate vs Alendronate

0.79 (0.38, 1.61)

50

1.22 (0.54, 2.28)

-48

1.91 (0.20, 7.43)

-60

3.48 (0.22, 16.27)

NR

Ibandronate vs Alendronate

1.13 (0.82, 1.60)

-83

1.00 (0.54, 1.69)

20,428

NR

NR

NR

NR

Ibandronate vs Etidronate

1.44 (0.68, 3.06)

-25

0.92 (0.37, 1.95)

121

NR

NR

NR

-22

Raloxifene vs Alendronate

1.12 (0.82, 1.55)

-90

1.28 (0.78, 1.98)

-38

2.47 (0.71, 6.55)

-38

2.60 (0.08, 11.84)

-39

Raloxifene vs Etidronate

1.41 (0.68, 2.96)

-27

1.17 (0.53, 2.29)

-62

2.76 (0.24, 11.66)

-32

1.87 (0.03, 9.82)

NR

Raloxifene vs Ibandronate

1.02 (0.70, 1.49)

-533

1.36 (0.71, 2.38)

-29

NR

NR

NR

-108

Risedronate vs Alendronate

0.95 (0.71, 1.23)

212

1.21 (0.79, 1.79)

-50

1.47 (0.62, 3.31)

-115

1.31 (0.10, 5.21)

3,328

Risedronate vs Etidronate

1.19 (0.57, 2.49)

-57

1.11 (0.52, 2.18)

-95

1.65 (0.18, 6.64)

-84

0.99 (0.03, 4.68)

NR

Risedronate vs Ibandronate

0.85 (0.60, 1.15)

70

1.29 (0.71, 2.19)

-36

NR

NR

NR

-25

Risedronate vs Raloxifene

0.84 (0.57, 1.15)

65

0.98 (0.61, 1.51)

622

0.79 (0.23, 1.96)

254

2.39 (0.05, 11.67)

-10

Strontium vs Alendronate

1.06 (0.81, 1.44)

-178

1.18 (0.78, 1.71)

-58

1.89 (0.61, 4.70)

-61

4.78 (0.14, 21.71)

NR

Strontium vs Denosumab

1.08 (0.75, 1.53)

-134

1.95 (1.20, 2.99)

-12

1.98 (0.44, 5.03)

-56

NR

-13

Strontium vs Etidronate

1.36 (0.65, 2.86)

-31

1.08 (0.51, 2.07)

-127

2.09 (0.20, 8.75)

-50

3.72 (0.05, 17.44)

NR

Strontium vs Ibandronate

0.95 (0.69, 1.34)

212

1.26 (0.70, 2.15)

-40

NR

NR

NR

-4

Strontium vs Raloxifene

0.94 (0.66, 1.34)

176

0.96 (0.60, 1.46)

243

1.03 (0.23, 2.66)

-1,789

10.85 (0.08, 41.99)

-6

Strontium vs Risedronate

1.12 (0.86, 1.57)

-90

0.99 (0.67, 1.43)

1,890

1.37 (0.44, 3.10)

-146

8.00 (0.15, 38.56)

-3

Strontium vs Teriparatide

1.38 (0.80, 2.35)

-29

1.99 (0.95, 3.66)

-11

4.92 (0.26, 24.44)

-15

19.69 (0.12, 80.47)

NR

Strontium vs Zoledronic Acid

1.17 (0.83, 1.66)

-64

2.17 (1.34, 3.34)

-10

1.93 (0.47, 4.98)

-59

NR

-49

Teriparatide vs Alendronate

0.77 (0.46, 1.31)

45

0.65 (0.31, 1.26)

28

1.35 (0.07, 5.71)

-154

1.69 (0.04, 8.09)

-102

Teriparatide vs Etidronate

0.98 (0.40, 2.30)

531

0.70 (0.39, 1.45)

24

1.54 (0.03, 9.01)

-100

1.33 (0.02, 6.65)

NR

Teriparatide vs Ibandronate

0.69 (0.40, 1.22)

33

0.53 (0.25, 0.98)

32

NR

NR

NR

-13

Teriparatide vs Raloxifene

0.68 (0.39, 1.19)

32

0.55 (0.26, 0.98)

21

0.76 (0.03, 3.27)

223

3.68 (0.02, 15.16)

-16

Teriparatide vs Risedronate

0.81 (0.49, 1.41)

55

0.55 (0.34, 1.04)

22

1.00 (0.05, 4.18)

NR

3.20 (0.04, 14.42)

NR

Zoledronic Acid vs Alendronate

0.91 (0.66, 1.30)

117

0.56 (0.34, 0.88)

22

1.24 (0.39, 3.16)

-225

NR

NR

Zoledronic Acid vs Etidronate

1.16 (0.55, 2.45)

-68

0.52 (0.23, 1.04)

20

1.38 (0.12, 5.70)

-142

NR

NR

Zoledronic Acid vs Ibandronate

0.82 (0.56, 1.19)

58

0.60 (0.31, 1.06)

25

NR

NR

NR

NR

Zoledronic Acid vs Raloxifene

0.81 (0.54, 1.19)

55

0.46 (0.26, 0.74)

18

0.68 (0.15, 1.78)

167

NR

NR

Zoledronic Acid vs Risedronate

0.96 (0.71, 1.41)

265

0.48 (0.29, 0.74)

18

0.91 (0.28, 2.07)

595

NR

NR

Zoledronic Acid vs Teriparatide

1.19 (0.68, 2.08)

-57

0.95 (0.45, 1.83)

216

3.11 (0.17, 16.12)

-26

NR

NR